# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX0...
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Annexon (NASDAQ:ANNX) with a Overweight.
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
- SEC Filing
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Annexon (NASDAQ:ANNX) with a Overweight.
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and maintains $12 price target.
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $11 to $13.
B of A Securities analyst Tazeen Ahmad maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $7 to $10.